Navigation Links
The Production and Marketing of IBS Drug Halted by the Chinese Government

The Chinese Food and Drug administration has put a halt to the production and marketing of Novratis AGs Zelnorm Drug, for irritable bowel syndrome, as the risk associated with it outweighs the benefits. The patients are asked to stop taking the medication.

The Chinese Drug watchdog posted a statement on its website warning risks of Zelnorm outweigh the possible benefits for some patients based on analyses from home and abroad." It is believed that the drug is linked to an increased risk of heart attacks and strokes.

The National Center for Adverse Drug Reaction Monitoring has received 98 reports of adverse reactions concerning Zelnorm since 2003 when the medicine was introduced to the Chinese market. The adverse reaction involved instances of Diarrhea and Nausea. One reported case was of abnormally fast heartbeat and another case of low blood pressure.

The Novrotis Drug was manufactured by three companies in China and is available in more than 20 provinces with thousands of users.

A review of data from 18,000 patients taking the medicine conducted by Novartis AG, Switzerland's largest drug maker, showed that a significant number had experienced cardiovascular problems. The company had complied with request from The American food and drug administration to with the Zelnorm drug from the market as it was linked with increased risk of heart attack, stroke and chest pain that can become a heart attack, the AP reported.

"We have announced this morning that we are complying with a request from the local authority to suspend the marketing and sales activity of (Zelnorm) in China," Novartis spokeswoman Corinne Hoff said. "More than 85 percent of our sales were in the U.S," she said. "I cannot give you the sales figures for China, but it's not significant," Hoff said.


Page: 1

Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Tea Found To Boost Insulin Production And Prevent Cataract
3. Conroy’s May Not Be Permitted To Resume Production Soo
4. Massive Production Of Bird Flu Vaccine To Be Initiated In China
5. Chugai Pharmaceutical To Initiate Domestic Production Of Bird Flu Vaccine
6. Coca Cola To Enhance Production Of Diet Coke
7. Natco Pharma Commences Production At Dehradun Unit
8. New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine
9. ABCB6 Is Key to Production of Heme in Hemoglobin
10. Drug Boosts Platelet Production, Reversing Immune Thrombocytopenic Purpura
11. High-Tech Microbes Bolsters Natural Sweetener Production
Post Your Comments:

(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: